drugset / Trial / NCT00073840

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073840

Phase 3 Completed 386 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).

Timeline

Start
2002-12
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levalbuterol Other / unclassified 90 ug Inhaled
Subject racemic albuterol Unknown 180 ug

Indications